Identification of a ligand-binding site on tubulin mediating the tubulin–RB3 interaction
Proceedings of the National Academy of Sciences · 18.03.2025 · 122 (11)
DOI: 10.1073/pnas.2424098122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 11.03.2025. Verfasst von Yong Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, State Key Laboratory of Biotherapy and Cancer Center, West China H…. Hauptthemen laut MEDLINE: Tubulin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
For decades, microtubules—composed of αβ-tubulin dimers—have been primary targets for cancer chemotherapy. While eight binding sites on the tubulin dimer have been structurally characterized, this study reveals a ninth. We found that the tubulin inhibitor Tumabulin-1 (TM1, a BML284 derivative) binds simultaneously to the well-known colchicine site and a previously unknown site, designated as Tumabulin site. This site resides at the interface of α1-tubulin, β1-tubulin, and RB3 within the tubulin–RB3–tubulintyrosine ligase complex. Remarkably, two TM1 molecules bind cooperatively to this relatively large pocket, interacting with all three proteins. Crucially, this binding is dependent on RB3; it is absent when RB3 is missing or the key residue H71 is mutated (H71Q). We further designed and synthesized Tumabulin-2 (TM2) that selectively binds the Tumabulin site, excluding binding the colchicine site. TM2 acts as a molecular glue, strengthening the interaction between RB3 and the tubulin dimer and consequently enhancing RB3’s tubulin-depolymerizing activity. In conclusion, our findings confirm the existence of a ninth tubulin-binding site and offer a promising foundation for developing Tubulin–RB3 molecular glues as a next generation of anticancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan Un…
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Natural and Biomimetic Medicine Research Center, Tissue-Orientated Property of Chinese Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
ORCID-Profile: Yong Li, Dongmei Tang, Tao Wang, Heying Pei, Qiang Chen, Jianhong Yang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Li, Y., Zhang, C., Tang, D., Wang, T., Yan, W., Yang, L., Bai, P., Tang, M., Pei, H., Chen, L., Chen, Q., & Yang, J. (2025). Identification of a ligand-binding site on tubulin mediating the tubulin–RB3 interaction. Proceedings of the National Academy of Sciences, 122(11). https://doi.org/10.1073/pnas.2424098122
Vancouver
Li Y, Zhang C, Tang D, Wang T, Yan W, Yang L, et al. Identification of a ligand-binding site on tubulin mediating the tubulin–RB3 interaction. Proceedings of the National Academy of Sciences. 2025;122(11). doi:10.1073/pnas.2424098122
BibTeX
@article{Li2025,
author = {Li, Yong and Zhang, Chufeng and Tang, Dongmei and Wang, Tao and Yan, Wei and Yang, Linyu and Bai, Peng and Tang, Minghai and Pei, Heying and Chen, Lijuan and Chen, Qiang and Yang, Jianhong},
title = {Identification of a ligand-binding site on tubulin mediating the tubulin–RB3 interaction},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {11},
doi = {10.1073/pnas.2424098122}
}
EUVIMED